Market Newsdesk

VANCOUVER, British Columbia, Dec. 14, 2020 (GLOBE NEWSWIRE) — Zadar Ventures Ltd. (the “Company”) (TSX. V – ZAD) (OTCQB – ZADDF) (Frankfurt – ZAV0.F) would like to take this opportunity to update its current and future shareholders. We are pleased to announce that we have received shareholder approval for the proposed acquisition by the Company of XRApplied SAS, which was announced July 31, 2020.

We have also filed a preliminary listing statement with the CSE under the name XRApplied Technologies Inc (“XRA”). Under the terms of our agreement, we will raise a minimum $700,000 and a maximum $3,500,000 at a price of $0.35 per unit by way of a non-brokered accredited investor private placement. Each unit consists of one common share and one share purchase warrant exercisable at $0.75 during the first year and $1.00 the second year.

The Company is excited to launch its new corporate website – www.xrapplied.com

About XRApplied Technologies Inc. (XRA)

XRA is an immersive technology solutions provider that specializes in bringing cost-efficient AR/VR e-commerce applications to businesses large and small. We accomplish this through a suite of proprietary products and services (AR catalog, toy gamification, AR App e-commerce, AR/VR interactive games) that we bring to the masses via our exclusive XRA Marketing Platform.

Company Chairman Mark Tommasi states, “We are thrilled to be moving forward with this acquisition in a time when AR/VR/MR technologies are disrupting every industry as we know it, and we strongly believe that we have found the right team and project to position us in this market. We are looking forward to launching a series of game changing business applications and consumer games in the AR/VR/MR space over the coming months.”

The Company advises that the transaction will acquire regulatory approval, and there is no assurance that the transaction will close. The Company will file all the necessary documents for approval of a change of business.

ON BEHALF OF THE BOARD OF DIRECTORS
Mark Tommasi
Chairman
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release may contain certain forward-looking information. All statements included herein, other than statements of historical fact, forward-looking information and such information involves various risks and uncertainties. There can be no assurance that such information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such information. Specifically, there is no assurance the Company will be able to (i) raise the necessary funds to close the transaction, (ii) obtain regulatory approval, or (iii) satisfy all conditions and close the transaction. The Company does not undertake to update any forward-looking information except in accordance with applicable securities laws.

ZADAR VENTURES LTD.

908-510 Burrard St
Vancouver, B.C. V6C 2A8
Phone: 604-682-1643

IRVINE, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) — Talonvest Capital, Inc., a boutique mortgage brokerage firm, negotiated a $59,500,000 refinance bridge loan on behalf of new client, LSC Development, LLC. The financing was secured by three recently constructed, Class-A storage facilities located in Oceanside, Garden City and Hewlett, New York. The non-recourse bridge loan was funded by a global investment management firm willing to offer 80%+ leverage based on the extensive experience of the sponsor, superior locations, and the quality of the assets. The loan included a 48-month term with extension options, and partial repatriation of ownership equity.  

All the properties benefit from irreplaceable locations in densely populated, yet substantially undersupplied trade areas on Long Island. The properties are insulated from the impacts of new supply as there is little to no developable land available due to the nature of these fully built out, mature New York submarkets. The assets, which are in various stages of lease-up, were developed by LSC and offer best-in-class design that quickly aided in accelerating leasing velocity.

Chris Barry and Jean Jodoin, Principals of LSC Development, commented, “This was our first experience working with Talonvest and we were impressed by their relationships and expertise.” John Nikolich of LSC added, “The Talonvest team negotiated hard on our behalf, were engaged throughout the process and delivered an attractive loan that closed quickly.” The Talonvest team representing LSC on this assignment included Kim Bishop, Jim Davies, Tom Sherlock, David Dirienzo, and Lauren Maehler.

About Talonvest Capital, Inc.:

Talonvest Capital, Inc. is a boutique real estate firm providing advisory services to commercial and self storage real estate investors, owners, and developers throughout the United States. The firm utilizes a unique collaborative team approach and four decades of institutional knowledge and expertise from the team members to deliver better capital solutions for its clients.

Contact:
Amanda Waite
Talonvest Capital, Inc.
949.648.0337
[email protected]

Geneva, Switzerland, December 14, 2020 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development announced today that it has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) for a proposed underwritten public offering of shares, including those to be settled in the form of American Depositary Shares (ADSs). Each ADS represents the right to receive six shares of Addex.  The terms of the offering have not been determined, and the offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed. The Company will be concurrently offering the shares in Europe (other than Switzerland) in a private placement to qualified investors, and in Switzerland through private placements.

H.C. Wainwright & Co. is acting as sole book-running manager for the offering.

The proposed offering will be made only by means of a prospectus. Once available, an electronic copy of the preliminary prospectus relating to, and describing the terms of, the offering may be obtained from H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by telephone at (646) 975-6996 or e-mail at [email protected] or on the SEC’s website.

A registration statement on Form F-1 relating to the proposed sale of these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. There is no intention or permission to publicly offer, solicit, sell or advertise, directly or indirectly, any securities of Addex Therapeutics Ltd in or into Switzerland within the meaning of the Swiss Financial Services Act (“FinSA”). Neither this document nor any other offering or marketing material relating to these securities, such as the shares, constitutes or will constitute a prospectus pursuant to the FinSA, and neither this document nor any other offering or marketing material relating to the shares constitutes a prospectus pursuant to the FinSA, and neither this document nor any other offering or marketing material relating to the shares may be publicly distributed or otherwise made publicly available in Switzerland.

About Addex Therapeutics:


Addex Therapeutics 
is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional “orthosteric” small molecule or biological drugs. Addex’s allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex’s lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is poised to start  a pivotal registration clinical trial for Parkinson’s disease levodopa induced dyskinesia (PD-LID) in 2021. Addex is also investigating dipraglurant’s therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in 2021. Addex’s third clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc, is scheduled to enter a phase 2a proof of concept clinical study for the treatment of epilepsy in 2021. Addex’s GABAB PAM program has been licensed to Indivior PLC for the treatment of addiction. Preclinical programs include GABA_B PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders. 

Press Contacts:

Tim Dyer Chief Executive Officer Telephone: +41 22 884 15 55 Email: [email protected]

Mike Sinclair Partner, Halsin Partners +44 (0)20 7318 2955 [email protected]

Forward Looking Statements:

Statements in this announcement concerning the timing and terms of the anticipated offering of the Company’s securities are forward-looking statements, which are subject to risks and uncertainties, including those risks described in the Company’s Annual Report on Form 20-F filed with the SEC on April 27, 2020, as well as market conditions and regulatory review.

Durham, NC, Dec. 14, 2020 (GLOBE NEWSWIRE) — ProcessMaker, a leader in enterprise workflow automation and business process management, and Typeform, a leading online form building software company, are unveiling a new workflow integration today for Typeform users.

This new integration allows Typeform users to easily turn their forms into powerful workflows with point-and-click functionality. Workflow for Typeform provides the ability to control workflows entirely from email and/or Slack, as well as create workflows with multiple levels of approvers, with the help of ad-hoc reassignment, workflow history logs, one-click reassignment and reporting.

“Typeform has a very unique approach to forms with their elegant, single-question style forms,” said Brian Reale, founder and CEO of ProcessMaker. “Many Typeform users have been looking for a way to  connect their Typeforms to business approval workflows – now they can do just that with Workflow for Typeform.”

Thousands of companies of all sizes collect data with Typeform. These companies will now have the ability to easily add workflows to their forms without coding.

“Typeform was founded on the belief that every interaction counts. With the Workflow for Typeform integration, the approval process is simplified on both sides, meaning fewer, and better, interactions. It’s a win-win,” said Francois Grenier, Head of Product Partnerships at Typeform.

Once a workflow, known as an “action,” has been set up, it is triggered by the submission of a Typeform and is completely dynamic. Further, multiple “actions” can be linked together to form more complex workflows. The workflow itself lives entirely in email and/or Slack and does not require anyone interacting with the workflow to login to software in order to make a decision or comment. With the history of the workflow appended to every request, each member of the workflow is fully informed to make the best possible decision.

Workflow for Typeform is now available to all Typeform users and provides the ability to add a critical layer of intelligent workflow to any Typeform. This new integration by ProcessMaker will give Typeform users the ability to create powerful form-based workflows in a matter of clicks.

To learn more about Workflow for Typeform, visit www.workflowfortypeform.com and the integration listing on Typeform Connect.

About Typeform

Founded in 2012 by David Okuniev and Robert Muñoz, Typeform transformed traditional online data collection methods into an intuitive, conversational experience, and put an end to boring, lifeless forms. With Typeform, people can easily create beautifully-designed, interactive, and mobile-optimized surveys & forms that people love to interact with, and with no technical experience necessary. One customer remarked, “It’s not just a form, it feels like a conversation.” Typeform currently employs 270 people and is headquartered in Barcelona, Spain, with an office in San Francisco, California. For more information, please visit www.typeform.com

About ProcessMaker

ProcessMaker is a low-code BPM and workflow automation platform. ProcessMaker makes it easy for business analysts to automate complex cross functional workflows  that connect people and existing company systems. Headquartered in Durham, North Carolina in the United States, ProcessMaker has a partner network spread across 35 countries on five continents. Hundreds of commercial customers, including many Fortune 100 companies, rely on ProcessMaker to digitally transform their core business processes enabling faster decision making, improved compliance, and better performance. 

 

Attachment

• Typeform-04

Matthieu McClintock
ProcessMaker
+1 (919) 289-1377
[email protected]